Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Argus Health
US Army
Covington
Merck
Daiichi Sankyo
Deloitte
Accenture

Generated: April 26, 2018

DrugPatentWatch Database Preview

Genzyme Corp Company Profile

« Back to Dashboard

Summary for Genzyme Corp
International Patents:165
US Patents:7
Tradenames:4
Ingredients:4
NDAs:5
Drug Master File Entries: 5

Drugs and US Patents for Genzyme Corp

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 RX Yes Yes 8,067,427 ➤ Sign Up Y ➤ Sign Up
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No 8,067,427 ➤ Sign Up Y ➤ Sign Up
Genzyme Corp CERDELGA eliglustat tartrate CAPSULE;ORAL 205494-001 Aug 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up
Genzyme Corp CERDELGA eliglustat tartrate CAPSULE;ORAL 205494-001 Aug 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Genzyme Corp

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme Corp HECTOROL doxercalciferol INJECTABLE;INJECTION 021027-002 Apr 6, 2000 5,602,116 ➤ Sign Up
Genzyme Corp HECTOROL doxercalciferol CAPSULE;ORAL 020862-001 Jun 9, 1999 5,869,473 ➤ Sign Up
Genzyme Corp HECTOROL doxercalciferol CAPSULE;ORAL 020862-003 Jul 13, 2009 5,602,116 ➤ Sign Up
Genzyme Corp HECTOROL doxercalciferol CAPSULE;ORAL 020862-001 Jun 9, 1999 5,602,116 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for GENZYME CORP drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 0.5 mcg and 2.5 mcg ➤ Subscribe 2009-03-25
➤ Subscribe Capsules 1 mcg ➤ Subscribe 2010-02-12
➤ Subscribe Injection 2 mcg/mL, 2 mL ampules ➤ Subscribe 2007-10-15
➤ Subscribe Injection 2 mcg/mL, 1 mL in 2 mL vial ➤ Subscribe 2011-12-28

Non-Orange Book US Patents for Genzyme Corp

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,890,949 Amino ceramide-like compounds and therapeutic methods of use ➤ Sign Up
6,255,336 Amino ceramide-like compounds and therapeutic methods of use ➤ Sign Up
5,952,370 Amino ceramide-like compounds and therapeutic methods of use ➤ Sign Up
6,414,148 Quinazoline derivatives and pharmaceutical compositions containing them ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Genzyme Corp Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0543 Netherlands ➤ Sign Up PRODUCT NAME: VANDETANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
/2015 Austria ➤ Sign Up PRODUCT NAME: ELIGLUSTAT, OPTIONAL IN DER FORM EINES PHYSIOLOGISCH AKZEPTABLEN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119
2015 00035 Denmark ➤ Sign Up PRODUCT NAME: ELIGLUSTAT, EVENTUELT I FORM AF ET FYSIOLOGISK ACCEPTABELT SALT, HERUNDER ELIGLUSTAT (SOM TARTRAT); REG. NO/DATE: EU/1/14/974 20150119
12/029 Ireland ➤ Sign Up PRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Teva
Moodys
Colorcon
Julphar
Medtronic
UBS
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.